Zusammenfassung
Radioaktive Substanzen werden zur Therapie verschiedenster gutartiger und bösartiger Erkrankungen eingesetzt. Grundsätzlich werden hierfür β-Strahler, selten auch α-Strahler verwendet, da diese im Gewebe eine sehr geringe Reichweite von wenigen Millimetern aufweisen und somit eine hohe Strahlendosis auf einem sehr begrenzten Raum erreicht werden kann.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Bayout JE, Macey DJ, Kasi LP, Fosella VJ (1994) Dosimetry and toxicity of 153-SM-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med 35: 63–69
Ben-Josef E, Porter AT (1997) Radioisotopes in the treatment of bone metastases. Ann Med 29: 3135
Bouchet LG, Bolch WE, Goddu SM et al. (2000) Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. J Nucl Med 41: 682–687
Bushnell DL, Manda Y, Williams RD et al. (2002) Efficiacy and safety of repeated samarium-153 lexidronam treatment in a patient with prostate cancer and metastatic bone pain. Clin Nucl Med 25: 698–700
Fischer M (1999a) Leitlinien für die Radionuklidtherapie bei schmerzhaften Knochenmetastasen. Nuklearmedizin 38: 270–272
Fischer M (1999b) Nuklearmedizinische Schmerztherapie bei metastasierten Karzinomen. Urologe (B) 39: 133–135
Fossa SD, Paus E et al. (1992) Strontium-89 in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes. Br J Cancer 66: 177–180
Haesner M, Buchali K, Pink V et al. (1992) Wirksamkeit der Therapie mit 89-Sr-Strontiumchlorid bei 200 Patienten mit Skelettmetastasen eines Prostatakarzinoms. Nucl Med 31: 48–52
Levington VJ (1996) Cancer therapy using bone-seeking isotopes. Phys Med Biol 41: 2027–2042
Malmberg I, Persson U, Ask A et al. (1997) Painful bone metastases in hormone-refractory prostate-cancer: economic costs of strontium-89 and/or external radiotherapy. Urology 50: 747–753
McEvan AJ, Amyotte GA, Mc Gowan DG et al. (1994) A retrospective analysis of the cost effectiveness of treatment with 89Sr-Cl in patients with prostatic cancer metastatic to bone. Nucl Med Comm 15: 499–504
McQuay Hi, Carroll D, Moore RA (1997) Radiotherapy for Painful Bone Metastases: A systematic review. Clin Oncol 9: 150–154
McQuay Hi, Moore RA (1998) An evidence-based resource for pain relief. Oxford University Press, Oxford New York
Pecher C (1942) Biological investigations with radioactive calcium and strontium: preliminary report on the use of radioactive strontiumin tratment of metastatic bone cancer. Univer Calif Publ Pharmakol 11: 117–149
Pons F, Herranz R, Garcia A et al. (1997) Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. Eur J Nucl Med 24: 1210–1214
Porter AT, McEvan EJ, Powe JE et al. (1993) Results of a randomised phase III trial to evaluate the efficency of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25: 805–813
Quilty PM, Kirk D, Bolger JJ et al. (1994) A comparison of the palliative effects of strontium-89 and external radiotherapy in metastatic prostate cancer. Radiother Oncol 31: 33–40
Resche I, Chatal JF, Pecking A et al. (1997) A dose-controlled study of 153-Sm-EDTMP in the treatment of patients with painful metastases. Eur J Cancer 33: 1583–1591
Robinson RG, Blake GM, Preston DF et al. (1989) Strontium-89 treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics 9: 271–281
Schoeneich G, Müller S, Palmeo H (1998) Indikation zur nuklearmedizinischen Therapie bei fortgeschrittenem Prostatakarzinom. Urologe (A) 37: 162–166
Serafini AN (2001) Therapy of metastatic bone pain. J Nucl Med 42: 895–906
Serafini AN, Houston SJ, Resche I et al. (1998) Palliation of pain associated with metastatic bone cancer using 153-Smlexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 16: 1574–1581
Silberstein EB (2000) Advances in our understanding of the treatment of painful bone metastases. J Nucl Med 41: 655–657
Silberstein EB, Williams C (1985) Strontium-89 therapy for the pain of osseous metastases. J Nucl Med 26: 345–348
Taylor AJ Jr (1994) Strontium-89 for the palliation of bone pain due to metastatic disease. J Nucl Med 35: 2054
Turner JH, Martindale AA, Sorby P, Hetherington EL et al. (1989) Sm-153 EDTMP therapy of disseminated skeletal metastasis. Eur J Nucl Med 15: 784–795
Windsor PM (2001) Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: Report of a single centre’s 10-year experience. Clin Oncol 13: 219–227
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Buschsieweke, U. (2004). Nuklearmedizin. In: Hankemeier, U.B., Krizanits, F.H., Schüle-Hein, K. (eds) Tumorschmerztherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18939-5_18
Download citation
DOI: https://doi.org/10.1007/978-3-642-18939-5_18
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62366-0
Online ISBN: 978-3-642-18939-5
eBook Packages: Springer Book Archive